-

Bristol Myers Squibb Announces Dividend

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on November 3, 2025, to stockholders of record at the close of business on October 3, 2025.

In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable on December 1, 2025, to stockholders of record at the close of business on November 4, 2025.

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.

corporatefinancial-news

Contacts

For more information, contact:

Media Relations:
media@bms.com

Investor Relations:
investor.relations@bms.com

Bristol Myers Squibb

NYSE:BMY

Release Summary
Bristol Myers Squibb Announces Dividend
Release Versions

Contacts

For more information, contact:

Media Relations:
media@bms.com

Investor Relations:
investor.relations@bms.com

More News From Bristol Myers Squibb

Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025...

Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum...

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology Congress 2025...
Back to Newsroom